Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.
Beam Therapeutics Total Payout Yield % Explanation
Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.
Beam Therapeutics Total Payout Yield % Related Terms
Beam Therapeutics Total Payout Yield % Historical Data
* Premium members only.
The historical data trend for Beam Therapeutics's Total Payout Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BEAM vs ELVN, IDYA, PBLS: Total Payout Yield % Comparison
For the Biotechnology subindustry, Beam Therapeutics's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics Total Payout Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's Total Payout Yield % distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's Total Payout Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics (MEX:BEAM) has a Total Payout Yield % of 0.02 as of Jul. 06, 2026. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Beam Therapeutics and its competitors.
Is Beam Therapeutics' Total Payout Yield % too high?
Beam Therapeutics' current Total Payout Yield % is 0.02. Overall, Beam Therapeutics has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Total Payout Yield % compare to ELVN and IDYA?
Beam Therapeutics' Total Payout Yield % of 0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Yield % for a Biotechnology company?
A good Total Payout Yield % depends on the Biotechnology industry context. However, Total Payout Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Yield % mean?
A high Total Payout Yield % can signal that a stock is expensive relative to its fundamentals. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Total Payout Yield % is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Fairly Valued. The stock's GF Value™ is MXN618.99, compared to a current price of MXN628.46 — trading 1.5% above its estimated fair value. The current Total Payout Yield % is 0.02. Beam Therapeutics' overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Yield % calculated?
Total Payout Yield % is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Total Payout Yield % is 0.02 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?
Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued.
The current stock price of MXN628.46 is trading 1.5% above its estimated GF Value™ of MXN618.99.
GuruFocus considers Beam Therapeutics to be Fairly Valued.
Key valuation signals for MEX:BEAM:
Total Payout Yield %: 0.02
GF Value™: MXN618.99 vs. price of MXN628.46 (1.5% above fair value)
No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
67GF Score
Get the complete analysis for MEX:BEAM
Total Payout Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BEAM has been successfully added to your 
